02162 KEYMED BIO-B
- 33.950
- +0.450+1.34%
KEYMED BIO-B News
Stock prices are falling on the eve of commercialization. When will Conoa-B (02162) remove the mountain Sanofi?
On April 25, Sanofi released its 2024 Q1 financial report. Of its total revenue of 10.464 billion euros, Dipriumab, the core product of the free free pipeline, contributed 2,835 billion euros, equivalent to 21.98 billion yuan. According to the annual report previously disclosed by Sanofi, the total global sales volume of the drug reached 11.5 billion US dollars in 2023. This sales volume is clearly out of reach for the domestic IL4R monoclonal circuit Gemini Conoa-B (02162) and Concord Biotech (CNTB.US), which have yet to commercialize their products. But after years of research and development, Connor, one of the twins
Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA
Keymed Biosciences (HKG:2162) said the National Medical Products Administration accepted its new drug application for Stapokibart injection for seasonal allergic rhinitis, according to a Tuesday filin
Conoa-B (02162.HK): The application for marketing licensing of drugs with spoximab injections to treat seasonal allergic rhinitis was accepted by the State Drug Administration
On April 30, Gelonghui | Conoa-B (02162.HK) issued an announcement. The application for marketing licensing of drugs with spiquimab injections to treat seasonal allergic rhinitis has recently been accepted by the China Drug Administration (“State Drug Administration”). This report is based on a multi-center, randomized, double-blind, placebo-controlled phase III study, which is mainly used to confirm the efficacy and safety of spiquivizumab injections for patients with seasonal allergic rhinitis in adults with poor control of nasal glucocorticoids or other treatments. The study results showed positive results from phase III clinical trial data, the main end point
Conoa-B (02162.HK): CM310 SAR phase III clinically successful product is expected to be approved within the year
Company News On April 28, the company announced that the phase III clinical trial of allergic rhinitis (SAR) during the CM310 treatment season has completed data deconstruction and statistical analysis of double-blind treatment period data, and clinical data has reached the main end point. Comments about CM3
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points
Keymed Biosciences (HKG:2162) said their Class 1 innovative drug CM310 for treating seasonal allergic rhinitis achieved its primary endpoints in a Phase III clinical study, according to a Sunday filin
Conoa-B (02162.HK): CM310 will soon be commercialized with differentiated pipeline layout in the early stages
Core view: (Unless otherwise specified, the following currencies are all RMB) The company issued the 2023 annual report performance announcement: revenue of 354 million yuan (+254% year over year, the following are all year-on-year caliber), mainly to authorize CMG to AZ
Conoa-B (02162): Phase III clinical trial of spoxibimab injection to treat seasonal allergic rhinitis reached the main end
Conoa-B (02162) issued an announcement. The company is pleased to announce that its Class 1 new drug, CM310, recombinant humanized monogram...
Conoa-B (2162.HK): Exclusive opportunity to reach the end of phase III allergic rhinitis
On April 28, the company revealed that the phase III clinical trial of sepcibimab for SAR had reached the main end point. On April 28, the company revealed that the phase III clinical trial of sepcibimab for SAR had reached the main end point. Among 108 subjects, the drug rTNSS
康諾亞-B：2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 6%, CM310 has submitted a listing application, and the company is welcoming the new commercialization cycle
Conoa-B (02162) rose more than 6%. As of press release, it had risen 6.17% to HK$30.95, with a turnover of HK$8.98,800.
Tencent recorded the biggest one-day increase in 10 months! The public offering group went south, and Zhang Kun and his team “overmatched” Hong Kong stocks
In the context of public fund giants collectively increasing their positions, Tencent Holdings recorded the biggest one-day increase in the last 10 months.
A quick look at the Hong Kong market | The three major indices have risen one after another. Technet stocks have generally risen, Tencent and Meituan have risen by more than 5%; Ideal has fallen by more than 8%
Many coal stocks fell sharply; Mongolian coking coal and China Coal Energy fell more than 6%; petroleum stocks fell, CNOOC Services fell more than 3%, and CNPC fell nearly 3%.
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 7% in the afternoon to complete a clinical trial of a drug to treat advanced solid tumors, completed the first case of the first test subject
Conoa-B (02162) rose more than 7% in the afternoon. As of press release, it was up 6.74% to HK$29.3, with a turnover of HK$404.85,500.
Conoa-B (2162.HK): The pipeline is progressing smoothly and is about to enter a new commercialization cycle
Description of the incident On March 26, 2024, the company released the 2023 performance report: the company achieved operating revenue of 354 million yuan for the full year of 2023, mainly including cooperative revenue generated by licensing to AZ; 2023
Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901
Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study
Keymed Biosciences (HKG:2162) said the first subject received the first dose of its advanced solid tumors drug on Thursday, according to a Friday Hong Kong bourse filing. Keymed Biosciences signed a d
Conoa-B (02162.HK): Renewed license agreement with ASTRAZENECA for CMG901 (AZD0901)
On April 12, GLONGHUI | Conoa-B (02162.HK) released an update on the licensing agreement between KYM Biosciences Inc. (“KYM”, a 70% non-wholly-owned subsidiary of the Group) and AstraZeneca AB (“AstraZeneca”, a global biopharmaceutical company) for the company's pipeline product CMG901 (AZD0901). In February 2023, KYM signed an exclusive global license agreement with AstraZeneca to develop and commercialize CMG901
Beijing has brought great benefits to innovative drugs!
In the middle of the night of April 7, the Beijing Municipal Medical Security Administration suddenly issued a “Notice on Public Consultation on the “Certain Measures to Support the High-Quality Development of Innovative Medicines by 9 Departments Including the Beijing Municipal Medical Security Administration (2024) (Draft for Comments)”. The public submission period for this consultation draft is only 3 working days. The first section of the clinical study clearly proposed reducing the overall time required to start a clinical trial to 28 weeks.
Conoa-B (2162.HK): CM310 is expected to be approved by the end of the year and multiple pipelines will continue to advance
Introduction to this report: The core product CM310 adult moderate to severe AD has been submitted for NDA. It is expected to be approved as the first domestic IL-4R monoclonal antibody by the end of 24. The R&D pipeline layout avoids cancer and continues to advance clinical, backup and industry
Analysis
Price Target
No Data
